Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$61000.0.

  • Pharma's Change in Receivables fell 48125.0% to -$61000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5000.0, marking a year-over-year increase of 9852.94%. This contributed to the annual value of $8000.0 for FY2025, which is 10253.97% up from last year.
  • Pharma's Change in Receivables amounted to -$61000.0 in Q3 2025, which was down 48125.0% from $53000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Change in Receivables peaked at $345000.0 during Q1 2022, and registered a low of -$301000.0 during Q1 2024.
  • Over the past 5 years, Pharma's median Change in Receivables value was $5000.0 (recorded in 2024), while the average stood at -$894.74.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 140869.57% in 2024, then surged by 58181.82% in 2025.
  • Over the past 5 years, Pharma's Change in Receivables (Quarter) stood at $25000.0 in 2021, then skyrocketed by 148.0% to $62000.0 in 2022, then plummeted by 170.97% to -$44000.0 in 2023, then surged by 111.36% to $5000.0 in 2024, then tumbled by 1320.0% to -$61000.0 in 2025.
  • Its last three reported values are -$61000.0 in Q3 2025, $53000.0 for Q2 2025, and -$2000.0 during Q1 2025.